课题基金 / 基金详情

Mechanisms of Human Lymphoid Chromosomal Translocation

Mechanisms of Human Lymphoid Chromosomal Translocation
人类淋巴染色体易位的机制
批准号:
10219165
负责人:
MICHAEL R LIEBER
金额:
$37.74万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-09-01 至 2022-08-31

项目摘要

项目成果

MICHAEL R LIEBER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
 DESCRIPTION (provided by applicant): Chromosomal translocations are the key inception point of many cancers and yet the molecular mechanism of translocations in humans is unclear. We have a unique database of 1,800 neoplastic chromosomal translocations from cancer patients for which the translocation junctions have been sequenced. We exploit these data from human B-cell lymphomas to define what is distinctive about the DNA regions where these patient translocations occurred. We have identified 7 well-defined DNA fragile zones that account for the majority of human B cell lymphomas. Although the translocations can potentially span 10-100 kb regions near oncogenes, the fragile zones we have identified are only 25-600 bp in length and are 100-1000-fold more susceptible to DNA breakage than nearby DNA. Determining the molecular and structural basis of these fragile zones is the major focus of this proposal. We have determined that all of the CG and WGCW sites within these fragile zones are sites of action of AID (activation-induced deaminase) which generates G:U base-pair mismatches by converting either C to U or methyl-C to T. The resulting base-pair mismatches can then be converted to double-strand DNA breaks (DSBs). None of the 7 human fragile zones we have identified are located in or near promoters, which is where translocations occur in murine models. Importantly, AID requires single-stranded DNA (ssDNA) as a substrate. Thus, one of our major goals is to determine what causes these 25-600 bp fragile zones to achieve a ssDNA state that leads to DSBs. All of the translocations studied in this proposal occurred during human pre-B cell differentiation. We have three sources of human pre-B cells for our analyses and two of these are primary cells. Aim 1 uses four parallel approaches to define the ssDNA character of the 7 fragile zones relative to nearby DNA. In Aim 1A & B, we identify regions of ssDNA using bisulfite and permanganate chemical probing. We will determine how well the location, length and degree of ssDNA character is correlated among the 7 fragile zones and what sequences and features (DNA repeats, protein binding motifs, DNA structural motifs) are in common among the 7 fragile zones. In Aim 1C we map all noncoding RNAs in human pre-B cells to determine whether noncoding RNAs are initiated at the boundaries of the 7 fragile zones to create topological tension. In Aim 1D, we test for altered DNA structures called R-loops in the fragile zones (Yu & Lieber, 2003). For Aim 2, we had already shown that the zones are fragile when moved to other nuclear locations, even in non-lymphoid human cells. New preliminary data in Aim 2 demonstrates that these zones are fragile in an extremely sensitive and quantitative genetic assay in S. cerevisiae. We show that the bcl-2 MBR is fragile only when transcription occurs through it and in a topologically-dependent manner. Aim 2A-C tests the other 6 fragile zones for transcription- and topologically-dependent fragility, and the effect of replication origin proximity. Aim 2D-E mutagenizes the bcl-2 MBR fragile zone to determine the minimal features and its sensitivity to activated Artemis. These studies are broadly relevant to fragile zones in all cells and tumors.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanisms of Human Lymphoid Chromosomal Translocation
  • 批准号:
    9756315
  • 项目类别:
  • 资助金额:
    $36.61万
  • 财政年份:
    2016
  • 负责人:
    MICHAEL R LIEBER
  • 依托单位:
Mechanisms of Human Lymphoid Chromosomal Translocation
  • 批准号:
    9099617
  • 项目类别:
  • 资助金额:
    $37.74万
  • 财政年份:
    2016
  • 负责人:
    MICHAEL R LIEBER
  • 依托单位:
Site-Specific Recombination in Human Health & Disease
  • 批准号:
    10162067
  • 项目类别:
  • 资助金额:
    $42.9万
  • 财政年份:
    2016
  • 负责人:
    MICHAEL R LIEBER
  • 依托单位:
Site-Specific Recombination in Human Health & Disease
  • 批准号:
    10400938
  • 项目类别:
  • 资助金额:
    $42.9万
  • 财政年份:
    2016
  • 负责人:
    MICHAEL R LIEBER
  • 依托单位:
海外基金